Snapshot as of end 2022
17
Pipeline
Projects
5
Innovation
Platforms
9
5
Licensing Deals
(since 2018)
About Us
17
5
9
Public and Private Collaborations
5
Licensing Deals
(since 2018)
Pipeline
EDDC aims to develop innovative therapeutics and companion diagnostics that have the potential to improve and save the lives of patients in Singapore and beyond. We want to advance the development of safe and effective therapies that address unmet medical needs.
We welcome partnerships with collaborators who share our vision, to jointly accelerate the development of our pipeline assets.
Find Out More About Drug Discovery
Playlist
Newsroom
- 28 July 2023
EARO Review (2020 – 2022) – A Review of EARO’s first 3 years
Recent News
- 26 July 2023
BioCurate and EDDC Signs MoU To Announce Strategic Alliance
- 26 May 2023
First Patient Dosed in Phase 1 trial of Antibody-Drug Conjugate EBC-129 in Patients with Solid Tumours
- 1 March 2023
Cancer Research Horizons and EDDC announce 5-year alliance
Partner with Us
EDDC is equipped with comprehensive capabilities for advancing the discovery and development of small molecule or antibody-based drugs, as well as companion diagnostics.
As a publicly-funded researcher, you can benefit from our extensive expertise and capabilities to advance your drug discovery project in various ways.
Consultancy
Services